OKYO Pharma Ltd. Form 6-K Summary
Reporting date: November 21, 2022. The filing is a report by a foreign private issuer under Form 6-K and includes Exhibit 99.1, a news service announcement.
Business Context
OKYO Pharma Ltd. announced the filing of a U.S. Investigational New Drug application for OK-101, its drug candidate for the treatment of dry eye disease.
Financial Information
The filing text does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes Versus Prior Period
The filing does not provide comparative financial information or identify changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide management guidance, financial outlook, clinical-development timelines, regulatory review expectations, risk disclosures, contingencies, or details regarding the status or contents of the U.S. IND filing beyond the announcement itself.
Key Facts to Verify
- Verify the full contents of Exhibit 99.1, which is referenced but not included in the provided filing text.
- Verify the precise status, scope, and acceptance or review of the U.S. IND filing for OK-101.
- Review subsequent filings for clinical-trial plans, regulatory milestones, financing needs, and available liquidity.
- Note that the Form 6-K states the attached Exhibit 99.1 is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act.